Indications, results and techniques of permanent prostate brachitherapy for localized trostate cancer;Braquiterapia de baja tasa en el tratamiento del cáncer de próstata localizado

Actas Urologicas Espanolas

Volumn 31, Issue 5, 2007, Pages 452-468

  Budia Alba A ^a   Bosquet Sanz, M ^a   Tormo Mico A ^a   Boronat Tormo, F ^a   Alapont Alacreu, J M ^a   Frances A ^a   Vera Donoso, C D ^a   Jimenez Cruz J F ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Prostate brachytherapy; Prostate cancer

Indexed keywords

EID: 34547195216     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(07)73668-9     Document Type: Review

References (90)

1. Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002; 12(1):81-94.
2. Pasteau O. Traitment du cancer de la prostate par le Radium. Rev Malad Nutr 1911:363-367.
3. Whitmore WF, Jr., Hilaris B, Grabstald H. Retropubic implantation to iodine 125 in the treatment of prostatic cancer. J Urol 1972; 108(6):918-920.
4. Carlton CE, Jr., Dawoud F, Hudgins P, Scott R Jr. Irradiation treatment of carcinoma of the prostate: a preliminary report based on 8 years of experience. J Urol 1972; 108 (6):924-927.
5. Holm HH, Juul N. Pedersen JF. Hansen H, Stroyer I. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983; 130(2):283-286.
6. Stone NN, Stock RG. Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation. Tech Urol 1995; 1(2):72-80.
7. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44(4):789-799.
8. Merrick G, Butler W, Lief J, Dorsey A. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:121-128
9. tone NN, Stock RG. Prostate brachytherapy in patients with prostate volumes >/= 50 cm(3): dosimetic analysis of implant quality. Int J Radiat Oncol Biol Phys 2000;46(5): 1199-1204.
10. Merrick GS, Butler WM, Dorsey AT, Lief JH. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol 2001;7(3): 233-240.
11. Merrick GS, Butler VVM, Wallner KE, Galbreath RW, Adamovich E. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004;64(4):754-759.
12. Terk M, Stock R, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998; 160:1379-1382.
13. Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002;60(4): 650-655.
14. Landis D, Wallner K, Locke J, Ellis W, Russell K, Cavanagh W, et al. Late urinary function after prostate brachytherapy. Brachytherapy 2002;1(1):21-26.
15. Hughes S, Wallner K, Merrick G, Miller S, True LD. Preexisting histologic evidence of prostatitis is unrelated to postimplant urinary morbidity. Int J Cancer 2001:96 Suppl:79-82.
16. Wallner K, Lee H, Wasserman S, Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997;37(3):565-569.
17. Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 1999;85(12):2630-2637.
18. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46 (4):839-850.
19. Dattoli M, Wallner K. True L, Sorace R, Koval J, Cash J, et al. Prognostic role of senun prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 1999;45(4):853-856.
20. Merrick GS, Butler WM, Lief JH, Galbreath RW, Adamovich E. Biochemical outcome for hormone-naive patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Cancer J 2002;8(4):322-327.
21. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 2000; 18(14):2740-2746.
22. Do TM, Parker RG, Smith RB, Kagan AR. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 2001;57(6):1121-1126; discussion 1126-1127.
23. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 2003; 169(5):1643-1652.
24. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology 2005;65(1):95-100.
25. Grann A, Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 1998;40(1):135-138.
26. Porter AT, Blasko, JC, Grimm PD, Reddy SM, Ragde H. Brachytherapy for prostate cancer. CA Cancer J Clin 1995; 45(3):165-178.
27. Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger PD. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1996;77(11):2386-2392.
28. Merrick GS, Butler WM, Dorsey AT, Lief JH. The dependence of prostate postimplant dosimetric quality on CT volume determination. Int J Radiat Oncol Biol Phys 1999; 44(5):1111-1117.
29. Badiozamani KR, Wallner K, Cavanagh W, Blasko J. Comparability of CT-based and TRUS-based prostate volumes. Int J Radiat Oncol Biol Phys 1999;43(2):375-378
30. Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol 1999;162(2):421-426.
31. Merrick GS, Butler WM, Lief JH, Dorsey AT. Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer? Tech Urol 2001;7(1):12-19.
32. Grimm PD, Blasko, JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51(1):31-40.
33. Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;47(5):1261-1266.
34. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173(5):1562-1566.
35. Merrick GS, Butler WM, Galbreath RW, Lief JH. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001:51(1):41-48.
36. Critz FA, Williams WH, Levinson AK, Benton JB, Holladay CT, Schnell FJ, Jr. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol 2000; 164(3 Pt 1):738-41; discussion 741-743.
37. Blasko JC, Wallner K. Grimm PD, Ragde H. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995; 154(3):1096-1099.
38. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 1998;280(11):969-974.
39. Kwok Y, DiBiase SJ, Amin PP, Naslund M. Sklar G, Jacobs SC. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002;53(3):588-594.
40. Battermann JJ, Boon TA, Moerland MA. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 2004:71(1):23-8.
41. Wallner K, Blasko J, Dattoli M. Prostate Brachytherapy made complicated. 2nd ed. Seattle; 2001.
42. Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000;48(1):111-117.
43. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 1251odine brachytherapy for prostate cancer. J Urol 2005;173(3): 803-837.
44. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337(5):295-300.
45. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed Implantation. Int J Radiat Oncol Biol Phys 2002;52(2):444-452.
46. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54(2):450-456.
47. Stone N, Stock R. Complications following permanent prostate brachytherapy. Eur Urol 2002;41:427-433.
48. Mallick S, Azzouzi R, Cormier L, Peiffert D, Mangin P. Urinary morbidity after 1251 brachytherapy of the prostate. BJU 2003;92:555-558.
49. Desai J, Stock RG, Stone NN, Iannuzzi C, DeWyngaert JK. Acute urinary morbidity following 1-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 1998; 6(3):135-141.
50. Gelblum D, Potters L, Ashley R, Waldbaum R, Wang X, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45:59-67.
51. Sarosdy M. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or. Cancer 2004;101:754-760.
52. Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52(2):453-460.
53. Locke J, Ellis W, Wallner K, Cavanagh W, Blasko J. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. Int J Radiat Oncol Biol Phys 2002; 52(3):712-719.
54. Kollmeier MA, Stock RG, Cesaretti J, Stone NN. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 2005;173(3):808-812.
55. Hirshberg ED, Klotz LH. Post transurethral resection of prostate incontinence in previously radiated prostate cancer patients. Can J Urol 1998;5(2):560-563.
56. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma J Clin Oncol 1996;14:449-453.
57. Pérez Romasanta L. Grados de toxicidad de la RTOG/EORTC.
58. Prada P, Hevia M, Juan G, Abascal J, De la Rua A, Abascal R et al. Braquiterapia de baja tasa (I125) en el cáncer de prostata localizado. Preliminary results after 5 years. Arch Esp Urol 2005;58:213-226.
59. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32(2):465-471.
60. Talcott J, Clark J, Stark P, Mitchell S. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001;166:494-499.
61. Stone N, Ratnow E, Stock R. Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech Urol 2000:123-127.
62. Blasko JC, Radge H, Grimm PD. Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol 1991;137:113-118.
63. Mabjeesh N, Chen J, Beri A, Stenger A, Matzkin H. Sexual function after permanent 125I-brachytherapy for prostate cancer. Int J Impot Res 2005;17:96-101.
64. DiBiase S, Wallner K, Tralins K, Sutlief S. Brachytherapy radiation doses to the neurovascular bundles. Int J Radiat Oncol Biol Phys 2000;46:1301-1307.
65. Kiteley R, Lee W, deGuzman A, Mirzaei M, Mc Cullough D. Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. Brachytherapy 2002;1:90-94.
66. Merrick G, Wallner K, Butler W, Galbreath R, Lief J, Benson M. A comparision of radiation doe to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys. 2001;50:597-604.
67. Robinson J, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54:1063-1068.
68. Benoit R, Naslund M, Cohen J. Complications after prostate brachyterapy in the medicare population. Urol 2000; 55:91-96.
69. Chrouser K, Leibovich B, Sweat S, Larson D, BJ. D, Tran N. Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol 2005;173:1953-1957.
70. Shah S, Cima R, Benoit E, Breen E, Bleday R. Rectal complications after prostate brachytherapy. Dis Colon rectum 2004;47:1487-1492.
71. Moreira S, Seigne J, Ondorica R, Marcel J, Pow-sang J, Lockhart J. Devasting complications after brachytherapy in the treatment of prostate adenocarcinoma. BJU 2004; 93:31-35.
72. Yurdakul G, de Reijke T, Blank L, Rauws E. Rectal squamous cell carcinoma 11 years after brachytherapy for carcinoma of the prostate. J Urol 2003;169:280-285.
73. Nag S, Ellis RJ, Merrick GS, Bahnson R, Wallner K, Stock R. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54(2):462-470.
74. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001;51(3): 614-623.
75. Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer 2001;91(11):2046-2055.
76. Brandeis JM, Litwin MS, Burnison CM, Reiter RE. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000;163(3):851-857.
77. Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001;166 (3):947-952.
78. Henderson A, Laing RW, Langley SE. Quality of life following treatment for early prostate cancer: does low dose rate (LDR) brachytherapy offer a better outcome? A review. Eur Urol 2004;45(2):134-141.
79. Beyer DC, Priestley JB, Jr. Biochemical disease-free survival following 1251 prostate implantation. Int J Radiat Oncol Biol Phys 1997;37(3):559-563.
80. Stokes SH, Real JD, Adams PW, Clements JC, Wuertzer S, Kan W. Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997;37(2):337-341.
81. Grado GL, Larson TR, Balch CS, Grado MM, Collins JM, Kriegshauser JS, et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998;42(2):289-298.
82. Sharkey J, Chovnick SD, Behar RJ, Perez R, Otheguy J, Solc Z, et al. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. Urology 1998;51 (5):796-803.
83. Storey MR, Landgren RC, Cottone JL, Stallings JW, Logan CW, Fraiser LP, et al. Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. Int J Radiat Oncol Biol Phys 1999;43(3):565-570.
84. Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000;89(1):135-141.
85. Ragde H, Grado GL, Nadir BS. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol 2001;54(7): 739-747.
86. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. W V Med J 2005;101 (4): 168-171.
87. Aguilo Lucia F, Suarez Novo JF, Correa Generoso R, Boladeras Inglada AM, Polo Rubio A, Pera Fabregas J, et al. Estudio retrospectivo de 130 pacientes con cáncer prostático organoconfinado tratados con braquiterapia prostática. Actas Urol Esp 2005;29(1):47-54.
88. Guinot JL, Estornell R, Escolar PP. What have we learned in the first two years about I-125 prostate brachytherapy? In: ESTROCongress, editor. Budapest: Radiother Oncol 75 supl (2005) S-36;2005.
89. Hu K, Wallner K. Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;40(4):783-186.
90. Koutrouvelis PG, Lailas N, Katz S, Sehn J, Gil-Montero G, Khawand N. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup. J Urol 2003; 169(4):1331-1336.